Sonnet BioTherapeutics
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Overlook Ctr, Princeton, New Jersey,...Phone Number
(609) 375-2227Website
www.sonnetbio.comRevenue
<$5 MillionStock Symbol
SONNIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
1
1
1
1
1
About Sonnet BioTherapeutics
Founded in 2015, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action.Explore more
Sonnet BioTherapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sonnet BioTherapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Sonnet BioTherapeutics launches new products
Earning: See what the market has to say on Sonnet BioTherapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Sonnet BioTherapeutics
Sonnet BioTherapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sonnet BioTherapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Sonnet BioTherapeutics has new funding data
Check if Sonnet BioTherapeutics has recently received funding, and reach out quickly before it becomes old news!
Check out if Sonnet BioTherapeutics is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Sonnet BioTherapeutics
Find 3 more new buyers
Compare Similar Companies to Sonnet BioTherapeutics
Compare insights from companies similar to Sonnet BioTherapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sonnet BioTherapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Sonnet BioTherapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Sonnet BioTherapeutics.
Sonnet BioTherapeutics financials insights
Gather financial insights about Sonnet BioTherapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Share Placement
$3.9M
Sonnet BioTherapeutics Tech Stack
A closer look at the technologies used by Sonnet BioTherapeutics
Most Recent Scoops
Promotion
Executive Move
Executive Moves, Promotion
New Hire
Executive Move
Executive Moves, New Hire
Lateral Move
Executive Move
Executive Moves, Lateral Move
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Earnings, Finance
Sonnet BioTherapeutics News & Media
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
PRINCETON, N.J., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced that it has adjourned its special meeting of stockholders (the “Special Meeting”) in order to provide stockholders additional time within which to vote on its proposed business combination (the “Business Combination”) with Hyperliquid Strategies Inc (“HSI”) and Rorschach I LLC (“Rorschach”), and the other proposals to be considered at the special meEvaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor microenvironment (TME) ex vivo to evaluate the effect of SON-1010 (IL-12-FHAB) in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers.Sonnet to Present at the MedInvest Biotech & Pharma Conference
Live webcast presentation on Thursday, September 25th at 9:40 AM PT Live webcast presentation on Thursday, September 25th at 9:40 AM PTSonnet Releases Virtual Investor "What This Means" Segment
- Dr. Richard Kenney, Chief Medical Officer of Sonnet, discusses the recently announced expansion of its clinical study of patients with platinum-resistant ovarian cancer (PROC) (SB221)
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sonnet BioTherapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2015, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action.... Read More
